Articles tagged with Drug Therapy
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
Researchers found that short-term MHT did not cause long-term cognitive decline in women in early postmenopause. The KEEPS Continuation Study suggests that timing is crucial for the safety of MHT.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers developed a novel lentivirus-based gene therapy strategy in CD34+ hematopoietic progenitor cells, which showed therapeutic levels of expression of the anti-sickling beta globin protein. Cyclosporin improved transduction efficiency and preserved cell viability.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
A new finger prick test for Alzheimer's disease has shown strong performance in a European study, measuring biomarkers in blood from superficial vessels. The test could soon be implemented globally, increasing accessibility to Alzheimer's testing without the need for high-sensitivity analyses.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A study reveals that nearly 137 million US adults are eligible for semaglutide therapy, more than the number eligible for statins. Semaglutide's broad eligibility could lead to increased adoption and treatment options for US adults.
A study found that pharmacists who received feedback about their heart failure patients increased the frequency of their patient interactions and prescribed more medication adjustments. The intervention, which provided educational resources and monthly audit and feedback emails, led to a significant increase in heart failure management.
Researchers found that ablation reduced ICD shocks for ventricular tachycardia and episodes of VT not detected by the ICD. This minimally invasive procedure destroys abnormal heart tissue causing VT, offering a better alternative to long-term medication side effects.
The international SUMMIT trial found tirzepatide lowered the risk of worsening heart failure events and cardiovascular death in obese adults with preserved ejection fraction. Participants experienced improved health status, physical function, and exercise tolerance compared to placebo.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
Researchers at St. Jude Children's Research Hospital identified a key role for glutamine in red blood cell development and disease. Glutamine metabolism plays a critical role in removing toxic byproducts, such as ammonium, that can accumulate during heme production.
Researchers discovered artemisinin partial resistance in Ugandan children with complicated malaria linked to the Pfkelch13 A675V genetic variation. This finding also highlights concerns over suboptimal treatment efficacy of parenteral artesunate followed by oral artemether/lumefantrine therapy.
Researchers at the University of Nottingham have discovered that GLP-1 receptor agonists may be effective in reducing alcohol consumption. The study suggests that this type of diabetes medication could potentially treat excessive alcohol use and lead to a reduction in alcohol-related deaths.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
A comprehensive review recommends computer-assisted cognitive-behavioral therapy (CCBT) and mobile mental health apps as a viable treatment option for depression and anxiety. Effective CCBT programs have been shown to reduce symptoms, while well-developed mobile apps can supplement in-person treatments.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
A new study found that GLP-1 agonists semaglutide and liraglutide were associated with reduced hospitalisations among individuals with alcohol use disorder. The use of these drugs was linked to lower risks of hospitalisation due to alcohol and substance use related causes, as well as physical illnesses.
The C-Path initiative aims to generate drug development solutions that reflect each person's unique experience, leveraging diverse data and innovative technologies like AI and digital health. GEM-PD seeks to address unmet need in Parkinson's disease therapies by focusing on sex and gender differences.
Researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases, two rare lysosomal storage disorders that cause progressive damage to nerve cells. The FDA-approved drug 4-phenylbutyric acid (4-PBA) showed significant improvements in motor function, lifespan, and healthy motor neurons.
Researchers found semaglutide and liraglutide substantially decrease AUD hospitalization risk compared to approved medications. Clinical trials are needed to confirm these findings and explore their efficacy in treating AUD.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
Researchers have developed a practical calculator to predict the risk of developing epilepsy after cerebral venous thrombosis, a rare cause of stroke. The tool is based on factors already available in clinical routine and can help inform treatment decisions or support preventive medication for those at high risk.
A new study found that beta blockers, commonly used to treat heart attack patients with normal pumping function, may lead to increased depression symptoms. Researchers observed more severe depression symptoms in patients who received beta blockers compared to those who did not.
Researchers at Tel Aviv University found that a special protocol of hyperbaric oxygen therapy can improve the condition of PTSD sufferers, reducing typical symptoms such as flashbacks, hypervigilance, and irritability. The study showed improvements in brain connectivity and clinical symptoms, offering new hope for millions of PTSD suff...
Scientists at Max Planck Institute for Intelligent Systems developed a novel method for deploying multiple magnetic miniature robots to navigate through complex networks resembling blood vessels. The system allows for simultaneous treatment of multiple locations, saving critical time and enabling localized care.
Researchers developed a 36-gene predictive score that surpasses conventional methods in predicting tamoxifen treatment resistance. The polygenic score UAB36 has potential as a tool for personalized medicine, helping identify patients at higher risk of poor survival and suggesting alternative treatment strategies.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Dr. Andreazza's work focuses on identifying biomarkers for personalized treatments in metabolic psychiatry, with breakthroughs in brain organoids and mitochondrial transplantation techniques. Her innovative approach aims to revolutionize treatment for both psychiatric and metabolic disorders.
Researchers at UCSD found psilocybin therapy reduces eating disorder psychopathology and improves quality-of-life in patients with anorexia nervosa, but results vary widely among individuals. Genetic variations may influence treatment outcomes.
Researchers from the University of Nottingham have discovered how a chemical produced by a caterpillar fungus interrupts cell growth signals in cancer cells. The study shows that cordycepin, found in these mushrooms, can be an effective treatment for cancer, potentially causing less damage to healthy tissues.
The partnership aims to simplify cooperation in ATMPs and related technologies, promoting research and development within academia, healthcare, and industry. The collaboration will explore opportunities for project and business development, quality-controlled production, and clinical trials.
The University of Central Florida has established a new research lab to advance light-based technologies for disease prevention, detection, and treatment. The interdisciplinary lab will facilitate collaborations between physicians, scientists, and researchers from various fields, including biophotonics and biomedical sciences.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
Researchers synthesizing AI with biomarker analysis aim to detect early signs of aging and enable targeted interventions to delay disease. This approach has the potential to slow, prevent or reverse certain effects of aging.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
Research reveals that antenatal corticosteroids can lead to smaller volumes of key brain areas in preterm infants, affecting emotion processing and motor control. The study suggests a delicate balance between benefits for respiratory health and potential risks to neurological development.
A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
The SynGAP Research Fund has awarded grants to Dr. Clement Chow to advance therapeutic development for SYNGAP1-Related Disorders. His research uses drug repurposing to identify compounds like N-acetyl-L-leucine as potential treatments.
Researchers used ex vivo lentiviral gene therapy to treat MPS IVA in mice, achieving partial correction of bone pathology and complete correction of heart pathology. The study suggests potential for novel therapies to treat patients with MPS IVA.
Researchers at UCLA have identified the protein GPNMB as a critical regulator in the heart's healing process after a heart attack. GPNMB promotes heart repair by binding to receptor GPR39, triggering a cascade of signals that limit scarring and improve cardiac function.
A CRISPR-Cas9 based gene editing therapy has been shown to reduce angioedema attacks and sustainably lower kallikrein levels in patients with hereditary angioedema, offering a potential treatment option. The therapy was tested on 27 patients across two dosages compared to placebo.
Researchers found that blood cancer cells rewired their gene regulatory networks to evade drug treatment in Acute Myeloid Leukemia (AML), disrupting normal differentiation and growth. The study identified key findings, including changes in open chromatin regions and the loss of binding of RUNX1 and AP-1 transcription factors.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
Researchers at NYU Langone Health develop antibodies that selectively target mutant HER2 cancer protein without harming healthy cells. The new treatment, a bispecific T cell engager, shows promise in reducing tumor growth with minimal side effects.
Dr. Fyodor Urnav proposes a set of initiatives to address the crisis, including pooling patients by syndrome and permitting multiple gene editors in a single Investigational New Drug application. This approach aims to accelerate the development of CRISPR therapies for rare genetic diseases.
Researchers at Emory University have discovered a family of enzymes that work to reduce IgG-mediated pathologies in diseases like Myasthenia Gravis. The newly found enzyme was used to treat various IgG-mediated pathologies in mice and found to be extremely effective, requiring only 4,000 times less of the enzyme than current treatments.
Researchers at the University of Sharjah have found that monoclonal antibodies can prevent asthma exacerbations and lower airway structural changes. The study suggests these treatments could be more effective than conventional therapies like steroids for patients with severe asthma.
Cognitive-behavioral therapy (CBT) is a promising intervention for addressing medical non-adherence in pediatric patients with chronic illnesses. CBT successfully integrates principles of learning theory and cognitive science to address behavioral and emotional challenges that affect health outcomes.
A randomized clinical trial found that montelukast did not shorten the duration of COVID-19 symptoms among outpatients with mild to moderate illness. The study's findings suggest that montelukast is unlikely to be beneficial for treating mild to moderate COVID-19.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
Researchers found that the oral medication palbociclib stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis, a form of appendix cancer often resistant to standard chemotherapy. The study's findings introduce a first targeted therapy for this rare disease.
A large-scale study of children with genetic disorders found that thousands benefited from targeted treatments and support after receiving a genetic diagnosis, with over 20% able to start or adjust therapies. Researchers expect this number to grow as new genetic therapies develop.
Researchers aim to develop small molecule drugs to target neuroinflammation in the brain, which contributes to cognitive decline. The goal is to slow or even cure Alzheimer's disease, offering a potential game-changer for the therapeutic landscape.
A new study suggests that introducing a smaller vial size for the Alzheimer's drug lecanemab could reduce waste by 74% and save Medicare up to $336 million per year. This is due to the high amount of unused medication being discarded, with each patient often receiving a dose lower than the available vial sizes.
The third annual TCT MedTech Innovation Forum will address pressing cardiovascular medicine challenges and unveil disruptive solutions. Visionary leaders from the medtech landscape will convene to explore bold solutions, share pioneering insights, and shape the future of cardiovascular care.
Researchers at Baylor College of Medicine discovered significant differences in bacterial metabolites between women with endometriosis and healthy controls, suggesting a non-invasive diagnostic test. A novel therapy based on the metabolite 4-hydroxyindole may also prevent endometriosis progression.